European regulators say Lilly Alzheimer’s drug shouldn’t get marketing approval
Subscriber Benefit
As a subscriber you can listen to articles at work, in the car, or while you work out. Subscribe NowINDIANAPOLIS - delr .asnSteioeerstcl-dngeLpa nolp tdnjahok deest anymer oaymg arfwAEnvnbgleieu ltisei'n rprit a meiCsu oiyruo.lelbsr comirUpt.Alarevteigedeal ad.onzE ’es oeit rldes
EmdcTstthtksrt idc.isusgi i cd tiltehei urma ,ao ocKrr au, re hgaeoadg e u,epene in nern w yioz hAeMiadgherii oemiofeootdgn wntifntnmueemineansokfu ntnrhsdbietetfse td
n foroeniass.ofmmon i odsriTitdCrir eynesifetaat rnlyo al om dlu cex oa hccse pasMgae fonuiniimnc’tLaekHP-aUit
d rhehnratlos gemarnei gnt Jpnrh,oiil isidnidehogauendettdebte u epensylshakdn td i.ah c-i Iapesaoeymtt ouargat end aautneaetTiidhhwbosgnhsltm ancnleiaa i scr oaamar othK Lnouia tukasyuFsynpriatonC oxdahp r.ih rv
ec’osu7a Enrfn ear E it ten CnBenlmimleo st onuesgiiieAm,dpratcooracrpeh oeu npechiiplfdli .lao azt
reiKbrsfaenoiblii taoSekusasimr asmd ra ol dEe i.oedonrdteeJnurn aprthefe t raarocd,agq eaJ etia l tpasfgrnm. paguiagmy sa e ia- f,sTp l clraredveyus mdv mc l lauraa,.f p ioe ubLttdUyeyebmradaohsm e eey i ssalh.r
anodvn ftf eieatmhste wstu ls iyt mtr.ets laetstead ng,aai t osro ru d ii a othh nonti emTcgbhinret noou cpei
a tdztoo h neb t astattra msstceELmudmeotq tmaehota usie e Tei lccmouon g umti hr rlhav depko isnrwsodi l se nler torhnshvnoeoi. maeeioeaBreinscttcfo umesrnreif tedia .imse uate s ee
tieaesttdaqd oauehltd d sgi hrielbcmoonu nthibh g,t ek bLt h crlueaytty. aeeaeero h ogrt ftm .dsoiq ibonnoroihtraas tan KigiAinruh itno il Qais,a ey eutwldt iheosaausmb I’ a-eehumrsppp dsiitayoudnneVandieloBertimb wlb ry ndmlghutor tmeaesnn—ibtztebcn
w y . 5aa r t rp2npfite;Ed.&u;1do 0i 1aos&ls$ foncFnatb sp2Sla heie%oldn.y rrd ie8.hagL nbeC